The market size for the
Biosymtec Monitor includes over 45 million people in the U.S. alone who should/must detect infections early.
For the standard Biosymtec Monitor the market size would include 34 million Americans with chronic illnesses. For the ObGyn version, the market size includes over 11 million women. The Biosymtec Initiative program, if adopted by the U.S.
government, will require millions of devices.
The initial marketing focus of Biosymtec Medical will be on the large patient populations with chronic illnesses.
COPD: 16 million in the U.S. alone have COPD and as many as 12 million more have undiagnosed COPD. COPD includes emphysema and chronic bronchitis. Over 60 million people around the world have moderate or severe COPD. COPD cost the U.S. around $30 billion dollars a year in healthcare expenses. Source: CDC
Asthma: 25 million have asthma, and the numbers are increasing every year. About 12 million with asthma have an asthma attack each year, many of which could have been prevented. Asthma cost the U.S. about $56 billion in medical costs. Source: CDC
CHF (Heart Failure): Almost 6 million adults in the United States have heart failure.
Nearly 10% of all deaths included heart failure as a contributing cause. About half of the people who develop heart failure die within 5 years of diagnosis. Heart failure costs the U.S. an estimated $30.7 billion each year. Source: CDC
Biosymtec™ technology will get these patients with chronic, life-threatening illnesses to their physician before the need for hospitalization, saving lives and significantly reducing healthcare costs.
Their physician's office will have a 50-day graph of the patient's data to review and pass on to the patient's physician before the patient even makes the call for an appontment!
From the patient to their physician in less than 120 seconds.